ArticleCJC open2026
Sociodemographic Characteristics Associated with PCSK9 Inhibitor Use in Individuals with Possible Familial Hypercholesterolemia in Alberta: A Cohort Study.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proprotein convertase subtilisin/kinase type 9 inhibitors (PCSK9is) significantly lower low-density lipoprotein cholesterol (LDL-c) level and improve cardiovascular outcomes, but they remain underutilized, potentially due to access-related barriers. This study examines clinical and sociodemographic factors associated with PCSK9i prescriptions in Alberta, Canada. Methods: A population-based study was conducted using data from the Alberta Kidney Disease Network. Adults with possible familial hypercholesterolemia (LDL-c ≥ 5 mmol/L) and suboptimal LDL-c control despite high-intensity statin therapy were included. Individuals with ≥ 3 dispensations of PCSK9i formed the treatment cohort. Multivariable logistic regression analysis was performed based on the identified variables, including neighbourhood income, material and social deprivation, sex, age, urban vs rural residence, and specialist involvement. Results: Among 15,286 eligible individuals, only 150 (0.98%) were prescribed PCSK9is. In multivariable analysis, those receiving PCSK9is were less likely to be female (adjusted odds ratio (OR) 0.50, 95% confidence interval (CI) [0.30, 0.81], Conclusions: PCSK9is are markedly under-prescribed in patients with severe hypercholesterolemia in Alberta. Prescription patterns have distinct differences by sex, specialist access, and neighbourhood income. Policy changes to improve equitable access, especially for disadvantaged populations, may help to reduce cardiovascular risk and improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.